Five things for pharma marketers to know: Thursday, August 27

The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision

CHC and CCC partner to offer regulatory education to agencies

The compliance "university" aims to help healthcare agencies and publishers stay up to date on the latest regulatory changes.

Mobile Marketing: Dial M for Launch

Mobile is the multilayered ecosystem into which all products are now launched, so doing it right is crucial to commercial and outcomes success. James Chase ...
Welcome to CampaignCheckup! CampaignCheckup is our new, monthly podcast series dedicated to examining the curious in Rx marketing and advertising. For our inaugural episode, "Cardiac Resuscitation," Larry Dobrow, senior editor, MM&M, and Michael Maher, president, ID Health, sit down to discuss the DTC campaign for Bristol-Myers Squibb's and Pfizer's oral blood thinner Eliquis.

Latest

Social Engagement: Leveling the Field

Social Engagement: Leveling the Field

Social media has the potential to elevate challenger brands to the highest step on the podium. But with many companies still languishing in the blocks, medal-worthy performances remain few and far between. It's time for pharma to step up its social game, as James Chase reports

What Wearables Can Deliver for Marketers

What Wearables Can Deliver for Marketers

Excitement about wearables like the Apple Watch or Fitbit sometimes fuels unrealistic hype about healthcare marketing opportunities.

Five things for pharma marketers to know: Wednesday, August 26

Five things for pharma marketers to know: Wednesday, August 26

Medicaid officials urged to expand access to hepatitis-C drugs; Perrigo is looking to make acquisitions; Sarepta's experimental therapy gets priority review

Brand Development Strategies: Golden Oldies

Brand Development Strategies: Golden Oldies

The rise of digital promotion and the need to wring every last drop of ROI from successful products have created a new niche: one with shoestring budgets, little to no sales-force support and competitors ready to pounce. Frank Celia explores late-lifecycle marketing and the companies and brands that manage to flourish there

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.

Inovalon scoops up consultancy Avalere Health

Inovalon scoops up consultancy Avalere Health

The cloud technology firm announced it will acquire Avalere in a move aimed at growing its relationships with pharma.

Five things for pharma marketers to know: Tuesday, August 25

Five things for pharma marketers to know: Tuesday, August 25

US patent office declines to review two Ampyra patents; the FDA expands indication for Promacta; the Biosimilars Council argues against CMS proposal for biosimilar coding

Patient Education/Marketing Report: Revolution

Patient Education/Marketing Report: Revolution

Patient education used to be a cookie-cutter operation: Hire a spokesperson, plan an event and draft a static list of symptoms, then call it a day. But in the wake of groundbreaking campaigns from AstraZeneca and Novartis, the industry may well have to raise its content-creation game—and cede considerable control to super-informed patients in the process. Larry Dobrow reports on the two programs that have raised the ­ patient-ed stakes

Will Pharma Have an Ashley Madison Moment?

Will Pharma Have an Ashley Madison Moment?

Ashley Madison's lesson must be heeded. For all the good pharma has done for the world, it has also created its share of ethical quagmires.

Publicis hangs out healthcare shingle in Singapore

Publicis hangs out healthcare shingle in Singapore

Publicis Healthcare Singapore will launch in September.

Five things for pharma marketers to know: Monday, August 24

Five things for pharma marketers to know: Monday, August 24

AstraZeneca inks cancer development deal; beta-blockers may increase survival in ovarian-cancer patients; OPDP finds corrective ads are ineffective

Experts: Sprout needs to show Addyi is not Viagra for women

Experts: Sprout needs to show Addyi is not Viagra for women

Contrary to popular belief, Addyi is not the female Viagra. That's the message drug-maker Sprout must get across to doctors and patients in the coming weeks.

Headliner: Sales vet keeps 111-year-old title spry

Headliner: Sales vet keeps 111-year-old title spry

Amy Clarke Luchsinger "thinks that HCPs want both digital and print. The people [she] talks with just want to be able to access information when and where they want it . . .

Five things for pharma marketers to know: Friday, August 21

Five things for pharma marketers to know: Friday, August 21

The FDA encourages clinical testing of testosterone; Google spins out its life-sciences business; Novartis buys remaining rights to Arzerra

The MM&M Weekly News Quiz: August 21

The MM&M Weekly News Quiz: August 21

Test your knowledge in this week's edition of the MM&M Weekly News Quiz.

Agency Spotlight



Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.